The oncoprotein SET is a potent inhibitor of the PP2A holoenzyme, whose levels are dramatically increased in primary chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) cells. Here, SET is linked to non-Hodgkin lymphoma.